Alex Thompson
Stock Analyst at Stifel
(3.99)
# 552
Out of 5,135 analysts
41
Total ratings
63.64%
Success rate
9.76%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Alex Thompson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ASND Ascendis Pharma | Maintains: Buy | $254 → $256 | $226.83 | +12.86% | 4 | Dec 11, 2025 | |
| ARGX argenx SE | Maintains: Buy | $1,028 → $1,248 | $845.35 | +47.63% | 5 | Dec 11, 2025 | |
| ANAB AnaptysBio | Maintains: Buy | $80 → $56 | $54.85 | +2.10% | 2 | Dec 11, 2025 | |
| DNTH Dianthus Therapeutics | Maintains: Buy | $52 → $65 | $47.47 | +36.93% | 2 | Sep 12, 2025 | |
| TVTX Travere Therapeutics | Maintains: Hold | $20 → $25 | $27.87 | -10.30% | 4 | Sep 12, 2025 | |
| CGEM Cullinan Therapeutics | Reinstates: Buy | $22 | $12.44 | +76.85% | 1 | Jun 11, 2025 | |
| KYMR Kymera Therapeutics | Reinstates: Buy | $55 | $85.11 | -35.38% | 1 | May 20, 2025 | |
| AVTX Avalo Therapeutics | Initiates: Buy | $36 | $15.00 | +140.00% | 1 | Mar 25, 2025 | |
| CRNX Crinetics Pharmaceuticals | Initiates: Buy | $60 | $43.43 | +38.15% | 1 | Mar 25, 2025 | |
| ORKA Oruka Therapeutics | Initiates: Buy | $49 | $32.27 | +51.84% | 1 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $36 → $54 | $36.60 | +47.54% | 2 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $6 → $2 | $13.96 | -85.67% | 5 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $66 → $69 | $18.45 | +273.98% | 2 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $2 → $1 | $3.17 | -68.45% | 4 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $40 | $28.11 | +42.30% | 2 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $320 | $57.74 | +454.21% | 1 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $34 | $26.65 | +27.58% | 2 | Jul 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $33 | $1.25 | +2,540.00% | 1 | Dec 14, 2022 |
Ascendis Pharma
Dec 11, 2025
Maintains: Buy
Price Target: $254 → $256
Current: $226.83
Upside: +12.86%
argenx SE
Dec 11, 2025
Maintains: Buy
Price Target: $1,028 → $1,248
Current: $845.35
Upside: +47.63%
AnaptysBio
Dec 11, 2025
Maintains: Buy
Price Target: $80 → $56
Current: $54.85
Upside: +2.10%
Dianthus Therapeutics
Sep 12, 2025
Maintains: Buy
Price Target: $52 → $65
Current: $47.47
Upside: +36.93%
Travere Therapeutics
Sep 12, 2025
Maintains: Hold
Price Target: $20 → $25
Current: $27.87
Upside: -10.30%
Cullinan Therapeutics
Jun 11, 2025
Reinstates: Buy
Price Target: $22
Current: $12.44
Upside: +76.85%
Kymera Therapeutics
May 20, 2025
Reinstates: Buy
Price Target: $55
Current: $85.11
Upside: -35.38%
Avalo Therapeutics
Mar 25, 2025
Initiates: Buy
Price Target: $36
Current: $15.00
Upside: +140.00%
Crinetics Pharmaceuticals
Mar 25, 2025
Initiates: Buy
Price Target: $60
Current: $43.43
Upside: +38.15%
Oruka Therapeutics
Oct 11, 2024
Initiates: Buy
Price Target: $49
Current: $32.27
Upside: +51.84%
Mar 26, 2024
Reiterates: Buy
Price Target: $36 → $54
Current: $36.60
Upside: +47.54%
Dec 18, 2023
Maintains: Hold
Price Target: $6 → $2
Current: $13.96
Upside: -85.67%
Dec 18, 2023
Maintains: Buy
Price Target: $66 → $69
Current: $18.45
Upside: +273.98%
Dec 18, 2023
Maintains: Hold
Price Target: $2 → $1
Current: $3.17
Upside: -68.45%
Sep 13, 2023
Reiterates: Buy
Price Target: $40
Current: $28.11
Upside: +42.30%
Aug 9, 2023
Initiates: Buy
Price Target: $320
Current: $57.74
Upside: +454.21%
Jul 18, 2023
Maintains: Buy
Price Target: $28 → $34
Current: $26.65
Upside: +27.58%
Dec 14, 2022
Initiates: Buy
Price Target: $33
Current: $1.25
Upside: +2,540.00%